Follitropin alfa sustained-release - Alkermes/Serono

Drug Profile

Follitropin alfa sustained-release - Alkermes/Serono

Alternative Names: Follitropin alfa-ProLease formulation - Alkermes/Serono; GONAL-f® micoencapsulated; Microencapsulated follitropin alfa; Microencapsulated rhFSH; ProLease® formulation rhFSH

Latest Information Update: 09 May 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono
  • Developer Alkermes
  • Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Female infertility; Male infertility

Most Recent Events

  • 30 Oct 2004 Discontinued - Phase-I for Female infertility in USA (SC)
  • 30 Oct 2004 Discontinued - Phase-I for Male infertility in USA (SC)
  • 24 Sep 2002 Phase-I clinical trials in Female infertility in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top